Clinical Trial Update: Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

An open-label, single-center, single-arm Phase 2 trial assessing neoadjuvant pembrolizumab in combination with carboplatin and paclitaxel for stage 1 cT1b-T1cN0…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Stage 1 cT1b-T1cN0M0, Triple Negative Breast Cancer | Phase 2 | Status: RECRUITING